Protocol Ledger

NCT07420283 · Phase II · RECRUITING

A Study of Brenipatide in Participants With Opioid Use Disorder

Interventional Phase II clinical trial protocol NCT07420283 sponsored by Eli Lilly and Company in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-13 Enrollment: 465 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07420283
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)465 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07420283
Protocol FieldVerified Registry Value
NCT IdentifierNCT07420283
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment465 participants (ESTIMATED)
Registered Start Date2026-02-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07420283
Hospital Research SiteLocationSite Profile
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI